我国基本药物筹资结构研究  

Study on the Financing Structure of Essential Medicines in China

作　　者：徐伟[1] 李梦姣[1] 曹晶晶[1] 李静[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药房》2014年第20期1825-1828,共4页China Pharmacy

基　　金：国家自然科学基金资助项目(No.71273278);教育部人文社会科学研究规划基金项目(No.11YJA790173)

摘　　要：目的：设计我国基本药物独立筹资结构，完善基本药物筹资机制。方法：分别以社会、个人和政府为出发点，以1836．5亿元作为我国基本药物的筹资标准，通过当前医保基金报销水平以及结余情况，推算出医保对于基本药物的筹资范围；并采用世界卫生组织／国际健康行动机构的方法定量测算出个人对基本药物的筹资上限；基于此，根据国民生产总值与财政收入的变动关系，结合国家财政收支状况评估财政补助对于基本药物筹资的可负担性。结果与结论：我国基本药物独立筹资结构，个人应以343．43亿元为上限，医保和财政的筹资范围分别为673．67～1028．82亿元和464．25～819．4亿元。照此结构，医保基金、个人以及政府财政均有较好的可负担性。且出于公平性的考虑，本研究建议个人按照人次均缴费的方式来为基本药物筹资。OBJECTIVE： To provide reference for the design of independent financing structure of essential medicines by com paring the capacity of personal, health care and finance, and dividing financing range of essential medicines based on the total amount of essential medicine financing for disease demands. METHODS： The study estimated the range of medicare funding for es sential medicines through the current medicare reimbursement levels and fund balances case, using 183.65 billion yuan as financing standard. WHO/HAI method was adopted to estimate the individual financing upper limit of essential medicine. Based on the above research, the affordability of financial assistance to essential medicines funding was evaluated according to national financial reve nue and expenditure. RESULTS ＆ CONCLUSIONS： For the independent financing of essential medicines, individual contributions should be based on a maximum of 34.343 billion yuan, health care and financial contribution ranges are 67.367- 102.882 billion yu an and 46.425-81.94 billion yuan. Considering about the fairness, recommended financing of essential medicines is by means of per capita payment by each person.

关 键 词：基本药物 独立筹资 结构 个人 医保 财政 

分 类 号：R95[医药卫生—药学]